Mirna Therapeutics, Inc. Company Profile
Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. The Company has a substantial body of pending intellectual property around miRNAs developed by its own scientists as well as in-licensed from other institutions. Mirnaâs IP portfolio contains >300 miRNAs with applications in oncology and other diseases. Oncology-directed miRNAs include those that are key tumor suppressors in cancer, such as miR-34 and let-7 that have proven to block tumor growth in a number of different pre-clinical animal studies. The Company, founded in 2007, is located in Austin, Texas. For more information, visit www.mirnarx.com.
News Articles
Deep in the heart of Texas: Mirna and ZS Pharma corral $80m combined in C fundings
Texas companies Mirna Therapeutics and ZS Pharma have roped in $34.5 million and $46 million respectively in separate Series C financings to advance liver and kidney disease drugs. Austin-based microR...
GW182 proteins cause PABP dissociation from silenced miRNA targets in the absence of deadenylation
GW182 proteins cause PABP dissociation from silenced miRNA targets in the absence of deadenylationGW182 proteins elicit miRNA-mediated translational repression through recruitment of the CCR4–NOT de...
Macro view of microRNA function in osteoarthritis
MicroRNAs (miRNAs) function in several chronic diseases—miRNA-mediated fine control of genetic networks involved in tissue development and homeostasis becomes disrupted. Participating in production...
[Mirna Therapeutics] raises $34.5mm through its Series C round
[Mirna Therapeutics Inc.] (microRNA therapies for cancer) has raised $34.5mm through its Series C round. Sofinnova Ventures led, and was joined by first-time investors New Enterprise Associates (NEA),...
Mirna Therapeutics secures $34.5 million Series C financing
Mirna Therapeutics announced the completion of a $34.5 million Series C financing. The company’s first institutional financing was led by Sofinnova Ventures, with participation from new investor...
Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis
Recent studies have identified correlations between cigarette smoke-induced microRNA (miRNA) expression and different aspects of lung cancer; however, it is unclear how miRNA expression directly contr...
Mirna Therapeutics Inc. (Austin, Texas) raised $34.5 million in a series C round led by new investor Sofinnova Ventures, with participation from new investors New Enterprise Associates; Pfizer Venture...
Drugs and Medications
None
PubMed Articles
The Promise of MicroRNA Replacement Therapy.
MicroRNAs (miRNA), a class of natural RNA-interfering agents, have recently been identified as attractive targets for therapeutic intervention. The rationale for developing miRNA therapeutics is based...
Kinetic Analysis Reveals the Fate of a MicroRNA following Target Regulation in Mammalian Cells.
Considerable details about microRNA (miRNA) biogenesis and regulation have been uncovered, but little is known about the fate of the miRNA subsequent to target regulation. To gain insight into this pr...
Inhibition of miRNA-221 Suppresses the Airway Inflammation in Asthma.
This study investigated the expression of miRNA-221 in asthmatics in order to determine whether miRNA-221 plays a role in the development of asthma. Real-time PCR was used to detect the miRNA-221 in b...
The activity and expression of microRNAs in prostate cancers.
Recent studies have shown that microRNA (miRNA) inhibitory activity can be quantified by examining their target mRNA expression levels. The accumulated evidence of differential miRNA activities betwee...
miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2.
Induced pluripotent stem cells (iPSCs) can be generated by overexpression of Oct4, Sox2 and Klf4 in murine fibroblasts. By conducting a microRNA (miRNA) library screen, we identified a set of miRNAs c...
Clinical Trials
microRNA Expression in Renal Cell Carcinoma
In this study, renal cell carcinoma (RCC) related miRNA and the target genes of related miRNA will be examined in order to investigate the role of miRNA in the formation of RCC and look fo...
Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C
Combination therapy with peginterferon plus ribavirin has become the current standard of care for chronic hepatitis C (CHC) patients, with an overall sustained virologic response (SVR) rat...
Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes
The "Lymphoscreen" study aims to characterize precisely (phenotypes/cytokines/functions) CD8+ T cell responses in type 1 Diabetes to identify biomarkers of the disease. Such markers are ne...
The Link Between Human Cytomegalovirus (HCMV) and Hypertension
It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity...
The Molecular Characterization of Multiple Myeloma at Relapse
Multiple myeloma (MM) is an incurable cancer. The disease can often be brought to a halt with chemotherapy which in younger patients is accompanied by stem cell transplantation. But the di...
Companies
Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. The Company has a substantial body of pending i...
Mirna Therapeutics, Inc. (Mirna) is a biotechnology company founded in late 2007 as a spin-off from Asuragen Inc. and is located in Austin, Texas. Mirna is focused on the developm...
Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. The Company has a substantial body of pending inte...
Asuragen is a molecular diagnostics company with a pioneering position in miRNA using genomics to drive better patient management through best-in-class clinical testing solutions....
Exiqon operates in two business segments sharing one vision: the idea of taking science to patients through personalized medicine; one focus: the promise of miRNA as biological markers; and one techno...
More Information about "Mirna Therapeutics, Inc." on BioPortfolio
We have published hundreds of Mirna Therapeutics, Inc. news stories on BioPortfolio along with dozens of Mirna Therapeutics, Inc. Clinical Trials and PubMed Articles about Mirna Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mirna Therapeutics, Inc. Companies in our database. You can also find out about relevant Mirna Therapeutics, Inc. Drugs and Medications on this site too.
